Seelos Therapeutics (SEEL) Stock Heads Up On Patent News

Seelos Therapeutics SEEL Stock News

Seelos Therapeutics Inc (NASDAQ: SEEL) is running for the top in the market this morning, trading on gains of around 5%. The gains come after the company announced that it has received a Notice of Allowance from the United States Patent and Trademark Office, or USPTO. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

SEEL Stock Climbs On Patent News

In the release, Seelos said that it received a Notice of Allowance for its US patent application (16/311,593). The application covers SLS-007, the company’s candidate that is being studied as a therapeutic option for Parkinson’s disease.

In the release, SEEL said that the allowed claims cover composition of matter comprising of at least one inhibitory peptide that inhibits alpha-synuclein aggregation. This inhibition happens by binding the residues 68-78 of a-synuclein.

The company also said that allowed claims cover a method of use for reducing of inhibiting a-synuclein aggregation, comprising contacting a-synuclein amyloid fibrosis with an inhibitory peptide in an amount sufficient to reduce or inhibit a-synuclein aggregation plus a method of modulating the size or rate of growth of a-synuclein amyloid fibrosis.

Importantly, at the end of the release, SEEL said that it is currently producing adeno-associated virus viral vectors. These vectors are being produced while the company is preparing animals for pre-clinical studies.

Why Investors Are Excited

There’s good reason that SEEL is working its way upward in the market. The truth of the matter is that Parkinson’s disease represents a large, unmet clinical need. Should Seelos be onto something here, it could be sitting on a goldmine.

However, before bringing any product to market, intellectual property protection is key. After all, if generic versions could hit the market as soon as the brand name version does, well the potential for revenue from the product would be killed.

So, with the announcement, investors see IP protection and are excited about the future here. Let’s not forget, the Parkinson’s disease market is expected to grow to be worth more than $8 billion annually by the year 2026. For a company like SEEL with a market cap of just $32 million, this opportunity is tremendous.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story!

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.